Auna, a leading Latin American healthcare platform with operations in Mexico, Peru, and Colombia, combines hospitals, oncology services, and health plans. The third-quarter 2026 results provide a useful test of whether the company can maintain commercial momentum while addressing profitability, especially in Mexico and Colombia. Recent periods have featured solid revenue gains alongside uneven margin trends, so it is worth monitoring whether cost pressures and contract issues prove temporary. With management set to host a 2026 Investor Day and having updated its outlook, this report gives a clearer picture of earnings quality, debt reduction, and cash generation across the three main markets.
Auna posted third-quarter 2026 revenue of S/1,325 million, up 10% year over year on an FXN basis and 19% as reported. Local-currency growth reached 16% in Mexico, 6% in Peru, and 12% in Colombia, supported by higher surgery and oncology volumes, complex procedures, and added hospital capacity. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Adjusted EBITDA declined 5% year over year on an FXN basis to S/231 million, holding flat as reported, with a margin of 17.5%. Segment adjusted EBITDA grew 5% in Mexico—its first year-over-year increase of 2026—but fell 6% in Peru and 30% in Colombia. Colombia’s drop reflected higher medical costs under a specific oncology risk-sharing contract that has since been terminated, plus regulatory price caps on certain high-cost oncology medications. Peru felt the impact of penalties linked to prior-year receivables reconciliations and a higher medical loss ratio.
Net income totaled S/24 million, down from S/53 million a year earlier, mainly because a S/40 million non-cash foreign-exchange gain from the prior period did not repeat. On a per-share basis, net income was S/0.27, while adjusted net income was S/35 million, or S/0.41 per share. Operating metrics remained positive: surgeries rose 12%, hospital days increased 6%, and chemotherapy and radiotherapy sessions grew 7%. Management kept full-year 2026 revenue guidance at 10%–14% FXN growth but now expects adjusted EBITDA to be broadly stable or slightly down year over year.
Investor reaction to Auna’s third-quarter 2026 report stayed measured. Top-line growth held steady and cash flow generation stood out, yet the drop in adjusted EBITDA and the steep decline in Colombia’s profitability drew attention. The decision to end the problematic oncology risk-sharing contract and the engagement of legal counsel to explore recovery options show management is addressing the issues, though near-term earnings pressure weighed on sentiment. Market data showed the stock trading lower after the release, with investors focusing more on margin durability than revenue momentum. The reaffirmed revenue outlook alongside softer adjusted EBITDA expectations framed the report as solid commercial expansion offset by ongoing profitability challenges.
Looking forward, Auna’s progress will hinge on restoring profitability in Colombia while keeping Mexico’s recovery on track. Ending the oncology risk-sharing contract removes one source of volatility, but it will be important to see whether legal recovery efforts produce results and how regulatory price caps develop. In Peru, attention stays on receivables reconciliation and the health-plan mix that has lifted the medical loss ratio.
Cash flow and leverage metrics will matter just as much. Year-to-date free cash flow growth and a leverage ratio moving toward 3.5x support the medium-term target of moving below 3.0x. Further debt reduction would strengthen the balance sheet and create room for growth investments.
Capital deployment and expansion projects also deserve watching, including the Centro Ambulatorio Trecca in Lima, a capital-light public-private partnership that management expects to provide longer-term revenue visibility. With full-year 2026 revenue guidance confirmed but adjusted EBITDA now projected to be broadly stable or slightly down, the central question is whether margin pressures ease soon enough to rebuild confidence in earnings growth.
When reviewing earnings like these, I often turn to Tickeron’s AI Screener to quickly filter peers and spot patterns in healthcare stocks. The tool helps me cross-check technical signals, fundamentals, and recent performance so I can place the quarter in better context without spending hours on manual screens. It has become a regular part of how I build and refine watchlists around earnings season.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The RSI Indicator for AUNA moved out of oversold territory on November 04, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 18 similar instances when the indicator left oversold territory. In 16 of the 18 cases the stock moved higher. This puts the odds of a move higher at 89%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 28 of 36 cases where AUNA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The Momentum Indicator moved above the 0 level on November 13, 2026. You may want to consider a long position or call options on AUNA as a result. In 44 of 57 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 77%.
The Moving Average Convergence Divergence (MACD) for AUNA just turned positive on November 17, 2026. Looking at past instances where AUNA's MACD turned positive, the stock continued to rise in 17 of 22 cases over the following month. The odds of a continued upward trend are 77%.
Following a +3.92% 3-day Advance, the price is estimated to grow further. Considering data from situations where AUNA advanced for three days, in 75 of 121 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.
AUNA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
AUNA moved below its 50-day moving average on October 22, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for AUNA crossed bearishly below the 50-day moving average on October 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 6 of 8 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 75%.
The 50-day moving average for AUNA moved below the 200-day moving average on November 03, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AUNA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 73%.
The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating fairly steady price growth. AUNA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 64 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.186) is normal, around the industry mean (204.532). P/E Ratio (21.273) is within average values for comparable stocks, (21.572). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.154) among similar stocks. P/S Ratio (0.289) is also within normal values, averaging (2.688).
The Tickeron SMR rating for this company is 89 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AUNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry HospitalNursingManagement